REPLIGEN CORP: directors' dealings · United States · SEC (Form 4)

About REPLIGEN CORP

Repligen Corp. (NASDAQ: RGEN) is a U.S.-listed life sciences company focused on bioprocessing technologies used in the manufacturing of biologic drugs. Headquartered in Waltham, Massachusetts, United States, the company operates as a specialized supplier of critical tools, consumables, and systems that support biopharma development and production. Repligen has a meaningful global footprint: while the majority of its manufacturing sites are in the U.S., it also maintains key sites in Europe and a growing presence in Asia. Its products are marketed globally through direct commercial teams in the United States, Europe, and Asia, as well as through selected partners and distributors. ([repligen.com](https://www.repligen.com/company/about?utm_source=openai)) Founded in 1981 by two scientists, Repligen has built its identity around innovation in bioprocessing. The company’s core mission is to help biopharmaceutical manufacturers reduce time, cost, and complexity in production while improving yield and product quality. This strategic positioning matters because the broader biologics market continues to expand, driven by the rise of biologic drugs, biosimilars, biobetters, and newer therapeutic modalities. Repligen’s business model is therefore tied to structural growth in outsourced and in-house biologics manufacturing rather than to a single end-market cycle. ([repligen.com](https://www.repligen.com/company/about?utm_source=openai)) From a business-line perspective, Repligen is organized around three main franchises: Filtration, Analytics, and Proteins. In Proteins, the company develops affinity ligands and chromatography resins used in purification workflows. In Analytics, it sells systems and devices used to monitor critical process parameters and product quality attributes during manufacturing. Its Filtration franchise rounds out the portfolio with solutions designed for purification and concentration steps in biologics production. This mix gives Repligen exposure to high-value, mission-critical stages of the biomanufacturing process and supports a differentiated competitive profile versus broader industrial suppliers. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai)) Repligen’s competitive positioning is based on proprietary products, customer intimacy, and a portfolio that has been broadened through both internal development and acquisitions. Management has emphasized innovation, commercial expansion, and operational scaling as key priorities. Recent company disclosures indicate that Repligen is targeting continued growth, with product launches across Analytics, Filtration, and Proteins, and with investments to expand its international support network. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2026/Repligen-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Financial-Guidance/default.aspx?utm_source=openai)) Recent milestones reinforce that strategy. In March 2025, Repligen acquired a bioprocess analytics portfolio from 908 Devices, adding products such as MAVERICK, MAVEN, REBEL, and ZipChip to strengthen its Analytics offering. In 2025 it also launched the CTech SoloVPE PLUS system. In February 2026, the company reported full-year 2025 revenue of $738 million and issued 2026 guidance calling for further growth and margin expansion. In April 2026, Repligen opened a European Training & Innovation Center in Breda, the Netherlands, underscoring its global customer-support ambitions. ([investors.repligen.com](https://investors.repligen.com/press-releases/news-details/2025/Repligen-Purchases-Bioprocessing-Analytics-Portfolio-from-908-Devices/default.aspx?utm_source=openai))